[PDF] Top 20 Cell therapy for autoimmune diseases

... The North American counterpart of the ASTIS trial, spon- sored by the National Institutes of Health – the ‘Scleroderma: Cyclophosphamide or Transplantation’ trial – compares safety and efficacy of a different transplant ... See full document

... stem cell therapy in the same way as many scientists hope that stem cells may be used to rebuild new ...in autoimmune disease is summarised in ... See full document

... A number of studies have shown that BM-derived MSCs can diff erentiate into cells expressing photo- receptor proteins when injected into the subretinal space [37,38]. Interestingly, it has been suggested that rat MSCs can ... See full document

... to autoimmune responses, although not usually considered classic IFNα- producing cells, neutrophils are capable of synthesizing this cytokine and other type I interferons in response to certain stimuli, including ... See full document

... are autoimmune skin blistering diseas- ...tory cell infiltration, and the linear deposition of IgG autoantibod- ies and complement components at the basement membrane zone ...epidermal cell ... See full document

... of diseases with a poor clinical outcome, and collectively categorized as “therapy-related myeloid neoplasms” (t-MN) in the 2008 World Health Organization (WHO) ...with autoimmune diseases; ... See full document

... of cell therapy, any modifications applied to the cell surface should not have detrimental effects on cell ...preparation, cell viability should be main- tained by changes in pH, ... See full document

... B cell depletion fol- lowing anti-CD20 therapy appears similar in these models, suggesting that they may provide clinically relevant ...anti-CD20 therapy in new-onset diabetic hCD20/NOD mice reversed ... See full document

... mice bearing NOD-derived regions, while reduced numbers of NKT cells in the livers of Idd4 (chromosome 11) congenic lines were reported. As the NOR strain of mice, which are closely related to the NOD strain (they share ... See full document

... The results reveal that an expert system to predict lupus is presented in this paper using Apriori and Neural Network Algorithm. Neural Network proves the better output which helps the domain experts for better diagnosis ... See full document

... other diseases, mostly neu- rodegenerative ...replacement therapy in mild to moderate Alzheimer’s disease, with subjects an average age of 75 years, yielded disappointing results with no significant effects ... See full document

... blistering diseases illustrates how impairments in epithelial adhesion lead to disorders characterized by substantial morbidity and/or mortal- ...Blistering diseases can be inherited or acquired; most ... See full document

... DENDROU, C.A., PLAGNOL, V., FUNG, E., YANG, J.H., DOWNES, K., COOPER, J.D., NUTLAND, S., COLEMAN, G., HIMSWORTH, M., HARDY, M., BURREN, O., HEALY, B., WALKER, N.M., KOCH, K., OUWEHAND, W.H., BRADLEY, J.R., WAREHAM, N.J., ... See full document

... 2. Fletcher JM*, Jordan MA*, Snelgrove SL, Slattery RM, Pellicci D, Besra GS, Godfrey DI and Baxter AG. Congenic Analysis of the NKT Cell Control Gene Nkt2 Implicates the Peroxisomal Protein Pxmp4. J. Immunol. ... See full document

... expression is negligible in B16F10 and LLC-1 cells, and IL-9 had minimal effects on growth in these cells [80, 81]. However, IL-9R expression is increased in EL-4 cells, indicating an additional effect of IL-9 on tumor ... See full document

... Tissues of the CNS, such as the brain, optic nerves, and spinal cord, may be affected by a range of insults includ- ing genetic, autoimmune, infectious, or neurodegenerative diseases and cancer. The immune ... See full document

... Stem Cell Transplantation International Scleroderma (ASTIS) trial in Europe and the American Scleroderma Stem Cell versus Immune Suppression Trial (ASSIST) and the Scleroderma: Cyclophosphamide or ... See full document

... white cell count and platelet count were ...B cell lymphoma) with expressing the CD20, PAX5, CD3, Bcl-2, kappa large cell, ki-67 40% and with no expression of the CD30, CD15, CD21 and ...B ... See full document

... B cell-activating factor; BCMA: B cell maturation antigen; BCR: B cell receptor; BILAG: British Isles Lupus Assessment Group; BLyS: B lymphocyte stimulator; Breg: B regulatory; ESSDAI: EULAR SS ... See full document

... combined therapy with abatacept and DMARDs within 6 ...background therapy for both groups of a steady dose of MTX), the response to abatacept was superior and was maintained for 3 years including physical ... See full document